A detailed history of Ubs Group Ag transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Ubs Group Ag holds 13,000 shares of BMRN stock, worth $875,939. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,000
Previous 385,542 96.63%
Holding current value
$875,939
Previous $31.7 Million 97.12%
% of portfolio
0.0%
Previous 0.01%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$69.02 - $93.84 $32.9 Million - $44.7 Million
476,429 Added 123.57%
861,971 $60.6 Million
Q2 2024

Aug 13, 2024

SELL
$74.43 - $92.22 $348 Million - $431 Million
-4,670,897 Reduced 92.38%
385,542 $31.7 Million
Q1 2024

May 13, 2024

BUY
$83.81 - $99.0 $416 Million - $491 Million
4,963,987 Added 5369.26%
5,056,439 $442 Million
Q4 2023

Feb 09, 2024

SELL
$76.22 - $98.51 $11.6 Million - $15.1 Million
-152,805 Reduced 62.3%
92,452 $8.91 Million
Q3 2023

Nov 09, 2023

SELL
$85.07 - $94.48 $2.1 Million - $2.34 Million
-24,719 Reduced 9.16%
245,257 $21.7 Million
Q2 2023

Aug 11, 2023

BUY
$86.68 - $100.3 $6.45 Million - $7.47 Million
74,431 Added 38.06%
269,976 $23.4 Million
Q1 2023

May 12, 2023

SELL
$87.74 - $117.27 $41.4 Million - $55.3 Million
-471,739 Reduced 70.7%
195,545 $19 Million
Q4 2022

Feb 08, 2023

SELL
$80.93 - $108.63 $35.4 Million - $47.6 Million
-437,947 Reduced 39.62%
667,284 $69.1 Million
Q3 2022

Nov 10, 2022

SELL
$82.16 - $96.94 $130 Million - $154 Million
-1,588,293 Reduced 58.97%
1,105,231 $93.7 Million
Q2 2022

Aug 10, 2022

SELL
$71.48 - $86.85 $12 Million - $14.6 Million
-167,979 Reduced 5.87%
2,693,524 $223 Million
Q1 2022

May 16, 2022

BUY
$74.28 - $92.69 $200 Million - $250 Million
2,697,524 Added 1645.04%
2,861,503 $221 Million
Q4 2021

Feb 14, 2022

SELL
$71.72 - $91.47 $9.58 Million - $12.2 Million
-133,514 Reduced 44.88%
163,979 $14.5 Million
Q3 2021

Nov 15, 2021

BUY
$74.77 - $85.47 $11.5 Million - $13.1 Million
153,667 Added 106.84%
297,493 $23 Million
Q2 2021

Aug 13, 2021

SELL
$75.51 - $84.79 $3.89 Million - $4.37 Million
-51,512 Reduced 26.37%
143,826 $12 Million
Q1 2021

May 12, 2021

BUY
$74.73 - $90.69 $4.88 Million - $5.92 Million
65,250 Added 50.16%
195,338 $14.8 Million
Q4 2020

Feb 11, 2021

BUY
$72.61 - $90.2 $3.31 Million - $4.12 Million
45,648 Added 54.06%
130,088 $11.4 Million
Q3 2020

Nov 12, 2020

SELL
$71.87 - $131.03 $2.89 Million - $5.27 Million
-40,207 Reduced 32.26%
84,440 $6.42 Million
Q2 2020

Jul 31, 2020

BUY
$79.55 - $124.22 $530,916 - $829,044
6,674 Added 5.66%
124,647 $15.4 Million
Q1 2020

May 01, 2020

SELL
$71.37 - $96.85 $1.88 Million - $2.55 Million
-26,296 Reduced 18.23%
117,973 $9.97 Million
Q4 2019

Feb 14, 2020

SELL
$64.27 - $86.37 $9.89 Million - $13.3 Million
-153,846 Reduced 51.61%
144,269 $12.2 Million
Q3 2019

Nov 14, 2019

BUY
$67.4 - $85.11 $10.1 Million - $12.7 Million
149,236 Added 100.24%
298,115 $20.1 Million
Q2 2019

Aug 14, 2019

SELL
$80.35 - $93.9 $1.55 Million - $1.82 Million
-19,346 Reduced 11.5%
148,879 $12.8 Million
Q1 2019

May 14, 2019

BUY
$84.2 - $98.62 $762,346 - $892,905
9,054 Added 5.69%
168,225 $14.9 Million
Q4 2018

Feb 14, 2019

SELL
$80.14 - $106.07 $933,550 - $1.24 Million
-11,649 Reduced 6.82%
159,171 $13.6 Million
Q3 2018

Nov 14, 2018

BUY
$93.92 - $105.72 $5.21 Million - $5.86 Million
55,475 Added 48.09%
170,820 $16.6 Million
Q2 2018

Aug 14, 2018

SELL
$76.01 - $99.03 $9.82 Million - $12.8 Million
-129,186 Reduced 52.83%
115,345 $10.9 Million
Q1 2018

May 15, 2018

BUY
$77.67 - $92.63 $4.98 Million - $5.94 Million
64,143 Added 35.56%
244,531 $19.8 Million
Q4 2017

Feb 14, 2018

BUY
$80.76 - $95.13 $2 Million - $2.36 Million
24,825 Added 15.96%
180,388 $16.1 Million
Q3 2017

Nov 14, 2017

SELL
$80.6 - $94.95 $1.97 Million - $2.32 Million
-24,469 Reduced 13.59%
155,563 $14.5 Million
Q2 2017

Aug 14, 2017

BUY
N/A
20,636 Added 12.95%
180,032 $16.4 Million
Q1 2017

Nov 14, 2017

BUY
N/A
159,396
159,396 $14 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.5B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.